esogno õhukese polümeerikattega tablett
g.l. pharma gmbh - eszopikloon - õhukese polümeerikattega tablett - 1mg 14tk; 1mg 28tk; 1mg 20tk; 1mg 98tk; 1mg 30tk; 1mg 100tk; 1mg 10tk; 1mg 56tk
esogno õhukese polümeerikattega tablett
g.l. pharma gmbh - eszopikloon - õhukese polümeerikattega tablett - 3mg 20tk; 3mg 98tk; 3mg 28tk; 3mg 100tk; 3mg 30tk; 3mg 10tk; 3mg 14tk; 3mg 50tk
lyumjev (previously liumjev)
eli lilly nederland b.v. - insuliin lispro - diabeet mellitus - diabeetis kasutatavad ravimid - suhkurtõve ravi täiskasvanutel, noorukitel ja 1-aastastel ja vanematel lastel. suhkurtõve ravi täiskasvanutel.
myrelez süstelahus süstlis
amdipharm limited - lanreotiid - süstelahus süstlis - 90mg 3tk
myrelez süstelahus süstlis
amdipharm limited - lanreotiid - süstelahus süstlis - 60mg 1tk; 60mg 3tk
meriofert set süstelahuse pulber ja lahusti
ibsa farmaceutici italia s.r.l. - menopausaalne humaangonadotropiin - süstelahuse pulber ja lahusti - 75rÜ 10tk; 75rÜ 1tk; 75rÜ 5tk
meriofert set süstelahuse pulber ja lahusti
ibsa farmaceutici italia s.r.l. - menopausaalne humaangonadotropiin - süstelahuse pulber ja lahusti - 150rÜ 5tk; 150rÜ 1tk
myrelez süstelahus süstlis
amdipharm limited - lanreotiid - süstelahus süstlis - 120mg 3tk; 120mg 1tk
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - mitu müeloomit - antineoplastilised ained - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
opexa silmatilgad, lahus
menarini international operations luxembourg s.a. - bilastiin - silmatilgad, lahus - 6mg 1ml 5ml 1tk